|Bid||5.86 x 800|
|Ask||5.84 x 4000|
|Day's range||5.79 - 6.49|
|52-week range||4.82 - 19.98|
|Beta (5Y monthly)||0.35|
|PE ratio (TTM)||N/A|
|Earnings date||10 Aug 2021 - 16 Aug 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||9.14|
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -53.57% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Shares of Wave Life Sciences (NASDAQ: WVE) are down 29% at 1:29 p.m. EDT after the company announced that WVE-120102 and WVE-120101, two of its drugs to treat Huntington's disease, failed to show an effect in early stage clinical trials. Huntington's disease is caused by different mutations in the huntingtin protein. WVE-120101 and WVE-120102 are designed to reduce the expression of mutant huntingtin protein (mHTT) for patients with the SNP1 and SNP2 mutations, respectively.
Investors need to pay close attention to Wave Life Sciences (WVE) stock based on the movements in the options market lately.